CA2109316A1 - Liposomal polysaccharide vaccines - Google Patents

Liposomal polysaccharide vaccines

Info

Publication number
CA2109316A1
CA2109316A1 CA 2109316 CA2109316A CA2109316A1 CA 2109316 A1 CA2109316 A1 CA 2109316A1 CA 2109316 CA2109316 CA 2109316 CA 2109316 A CA2109316 A CA 2109316A CA 2109316 A1 CA2109316 A1 CA 2109316A1
Authority
CA
Canada
Prior art keywords
adjuvant
antigen
liposome
polysaccharide
levan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2109316
Other languages
English (en)
French (fr)
Inventor
Edward Abraham
Yi-Han Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2109316A1 publication Critical patent/CA2109316A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA 2109316 1991-05-13 1992-05-13 Liposomal polysaccharide vaccines Abandoned CA2109316A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69914491A 1991-05-13 1991-05-13
US699,144 1991-05-13

Publications (1)

Publication Number Publication Date
CA2109316A1 true CA2109316A1 (en) 1992-11-14

Family

ID=24808131

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2109316 Abandoned CA2109316A1 (en) 1991-05-13 1992-05-13 Liposomal polysaccharide vaccines

Country Status (8)

Country Link
EP (1) EP0584212A4 (hu)
JP (1) JPH07500813A (hu)
AU (1) AU665762B2 (hu)
CA (1) CA2109316A1 (hu)
FI (1) FI934866A (hu)
HU (1) HUT67159A (hu)
NO (1) NO934106L (hu)
WO (1) WO1992020370A1 (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2180576T3 (es) * 1993-04-27 2003-02-16 United Biomedical Inc Construcciones peptidicas de lhrh inmunogenicas y estimuladores de inmunidad universales sinteticos para vacunas.
FR2716373B1 (fr) * 1994-02-23 1996-05-03 Pasteur Institut Liposomes, et leur utilisation pour l'obtention de vaccins.
EP0969826A1 (en) * 1997-03-11 2000-01-12 Stichting Dienst Landbouwkundig Onderzoek Use of liposomes containing a chelating agent, a fungicide or a secropine for improving mucosal vaccination
US6749831B1 (en) 1997-05-16 2004-06-15 Medical Defense Technology, Llc Vaccine against lipopolysaccharide core
US7534442B2 (en) 2001-08-21 2009-05-19 The Brigham And Women's Hospital, Inc. Immunogenic compositions comprising covalently bound polysaccharides, antigen, and bacterial toxoid
EP1928418B1 (en) 2005-09-30 2011-12-21 Lipoxen Technologies Limited Liposomal vaccine compositions comprising a polysaccharide antigen and a protein adjuvant
GB2548848A (en) * 2016-03-30 2017-10-04 The Inst Of Food Res Levan polysaccharide to modulate cell function

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199565A (en) * 1979-03-26 1980-04-22 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
JP3485184B2 (ja) * 1989-07-14 2004-01-13 アメリカン サイアナミド カンパニー インターロイキン含有安定ワクチン組成物

Also Published As

Publication number Publication date
HU9303207D0 (en) 1994-03-28
WO1992020370A1 (en) 1992-11-26
HUT67159A (en) 1995-02-28
EP0584212A4 (en) 1994-11-30
EP0584212A1 (en) 1994-03-02
AU1902992A (en) 1992-12-30
FI934866A0 (fi) 1993-11-03
AU665762B2 (en) 1996-01-18
NO934106L (no) 1994-01-12
NO934106D0 (no) 1993-11-12
FI934866A (fi) 1993-11-12
JPH07500813A (ja) 1995-01-26

Similar Documents

Publication Publication Date Title
Abraham et al. Intranasal immunization with liposomes containing IL-2 enhances bacterial polysaccharide antigen-specific pulmonary secretory antibody response.
Abraham Intranasal immunization with bacterial polysaccharide containing liposomes enhances antigen-specific pulmonary secretory antibody response
EP1476173A1 (en) Outer membrane vesicles from gram negative bacteria and use as a vaccine
Sedgwick et al. Induction of IgE-isotype specific tolerance by passive antigenic stimulation of the respiratory mucosa.
Beignon et al. Immunization onto bare skin with heat‐labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge
AU709221B2 (en) Immunomodulatory methods using oligosaccharides
US5013555A (en) Agent for desensitizing man and/or animals against an allergen
RU2526910C2 (ru) Профилактическая вакцина от туберкулеза
Geurtsen et al. Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice
CA2109316A1 (en) Liposomal polysaccharide vaccines
JP2747435B2 (ja) 肺炎球菌抗原の経鼻投与方法
KR101854904B1 (ko) 비피막형 헤모필루스 인플루엔자 백신 및 그의 용도
JP2002518343A (ja) ヘリコバクター感染に対する非経口的免疫処置法におけるｌｔおよびｃｔ
US6121427A (en) Major outer membrane protein CD of branhamella
EP1071452A1 (en) Vaccine compositions comprising cd-1 antigens and t-cell stimulating compound and methods of use thereof
De Moreno de LeBlanc et al. Oral administration of L. casei CRL 431 increases immunity in bronchus and mammary glands
VanCott et al. Induction of pneumococcal polysaccharide-specific mucosal immune responses by oral immunization
Watarai et al. Application of liposomes to generation of monoclonal antibody to glycosphingolipid: production of monoclonal antibody to GgOse4Cer
JP2008521871A (ja) ホスファチジルセリンおよび抗原またはアレルゲンを含む組成物、およびその使用
Yamamura et al. Experimental pulmonary cavity formation by mycobacterial components and synthetic adjuvants
JPH06507420A (ja) 粘膜の病原体に対するワクチンとその製法
JPH11240844A (ja) 肺炎球菌抗原の経口投与
JP2000507209A (ja) ボレリア・ブルグドフェリ（Ｂｏｒｒｅｌｉａ ｂｕｒｇｄｏｒｆｅｒｉ）抗原を投与するための組成物および方法
EP1019087A1 (en) Ganglioside immunostimulating complexes and uses thereof
Johnson Adjuvant Action of Bacterial Endotoxins on Antibody Formation: A Historical Perspective

Legal Events

Date Code Title Description
FZDE Dead